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ABSTRACT 
Objective: The aim of this work was to develop triple action controlled release anti-reflux suspension of ranitidine and its in-vitro evaluation of 
anti-reflux and controlled release properties. 
Methods: The formulation was optimized using sodium alginate as a gelling agent along with calcium carbonate, sodium bicarbonate, magnesium 
hydroxide, aluminium hydroxide as alkalizing agents and colloidal microcrystalline cellulose (MCC) as a suspending agent at various concentrations 
and arrived at an optimized formulation for its best quality attributes. To avoid initial release in water before administration, ranitidine coated MCC 
sphere was incorporated into powder formulation and subjected to in vitro characteristics like raft strength, acid neutralizing capacity, pH, viscosity 
and dissolution study. The obtained results were assessed using Minitab 17 statistical software to conclude the study design.  
Results: Formulation containing 300 mg of ranitidine along with 750 mg alginate has shown better anti-reflux characteristics like raft strength 
18±2g, acid neutralizing capacity 17±1 mEq compared to other formulations. This formulation has also shows zero-order controlled release in the 
simulated gastric fluid (SGF) up to 10 h compared to the formulation without alginate. Further, to this optimized formulation has shown negligible 
change in the assay of ranitidine even after 3 mo at 40 °C temperature and 75% RH.  
Conclusion: The developed stable sustained release powder for suspension has the combined therapeutic efficacy as an antacid and anti-reflux 
drug suitable for the management and treatment of gastro-oesophageal reflux disease (GERD) unlike the existing drugs possessing only reflux 
resistance action. 
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Anti-reflux formulation has been known since the last couple of decades. 
Alginate suspension plays a vital role in acting against refluxes in the 
management and treatment of gastro-oesophageal reflux disease 
(GERD) [1-3]. Alginate liquid suspension mainly acts against symptoms 
associated with GERD. Anti-reflux formulations are available in different 
dosage forms in the global market as a liquid suspension [3, 4] as 
granules [5] for suspension and as a chewable tablet [6]. A very few 
attempts have only been made towards the development of anti-reflux 
formulation and thus has a wide scope for further exploration. 
GERD is diagnosed with symptoms of acid reflux, in which stomach 
acid and content backs up into the esophagus resulting in heartburn, 
regurgitation. Long-term GERD can also bring about reflux 
esophagitis or Barrett’s oesophagus [1]. Pathophysiology of GERD 
makes the cardiac sphincter located at the upper part of the stomach 
lose its functionality, which would otherwise prevent the backflow 
of stomach content. Alginate and bicarbonate in the presence of acid 
forms raft that acts as a physical barrier and prevents the reflux in 
GERD. Alginate gets converted to alginic acid gel and bicarbonate 
liberates carbon dioxide in the presence of stomach acid. The 
evolved carbon dioxide gets entrapped into the gel-forming raft [7-
10]. Additionally, alginate has the favorable adhesion property that 
makes it adhere to the oesophageal tissue and help the raft to act 
strongly against acid refluxes [11].  
The challenges of the existing liquid dosage form can easily be 
overcome by alginate powder for suspension. The powder can be 
packed in a sachet as a single unit dosage form rather than a multi-
dosage form and can be easily administered. Sachet has better patient 
compliance with respect to handling and carrying. Moreover, powder 
dosage form has better stability than oral liquid suspension form. 
Anti-reflux suspension is generally used in combination with 
antacid, histamine type-2 receptor antagonists; promotility agent 
and a proton pump inhibitor for improved therapeutic benefits [12, 
13]. In order to overcome the poor solubility of alginate powder, 
microcrystalline cellulose and sodium carboxymethyl cellulose 
(CMC) a co-processed excipient (avicelCL611) was used as the 
suspending agent. The optimized formulation was tested for its 
physical attributes like raft strength, viscosity, pH, formation speed, 
floatation, acid neutralizing capacity [14]. Ranitidine was 
incorporated in alginate powder to form a powder for suspension and 
tested for its functionality. Ranitidine is widely prescribed in the 
treatment of GERD, and the recommended adult oral dosages are 150 
mg (b. i.d.) or 300 mg (q. d.), preferably 150 mg (q. i.d.). The conventional 
150 mg ranitidine can inhibit the acid secretion only up to 3-5 h and not 
for 10 h. The increase in dosage 300 mg, however, leads to plasma 
fluctuation [15]. This necessitates the development of a controlled 
release system for the treatment of GERD [16]. 
In this context, the present work was focused on the development of 
ranitidine alginate powder for suspension which controls the 
refluxes, neutralize the acid and reduce acid secretion in the 
stomach in GERD. This novel suspension reacts with stomach acid 
and neutralize the excess acid, raft act as a physical barrier and 
floats over stomach acid for several hours and continuously releases 
ranitidine in stomach thereby bringing about the desired three 
therapeutic effect in a single formulation. 
The results were assessed using Minitab statistical software. The 
formulation with alginate 750 mg was shown good physical quality 
attributes and further studied for in vitro dissolution in SGF up to 10h. 
MATERIALS AND METHODS 
Materials 
Ranitidine HClUSP/NF was generously donated by Umedica 
Laboratories Pvt. Ltd., Mumbai, India. Protanol L FR 5/60 USP/NF 
(sodium alginate), Avicel PH105 USP/NF (microcrystalline 
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cellulose), avicelCL611USP/NF (colloidal microcrystalline cellulose) 
was kindly provided by FMC Biopolymer, USA. sodium bicarbonate 
USP/NF manufactured by Innophos,scoraliteLL250 USP/NF 
(calcium carbonate), pharmacoat645 USP/NF (hypromellose) 
manufactured by SHIN-ET-SU, celsphereCP102 (MCC sphere) 
manufactured by Ashikasei, Japan and magnesium hydroxide 
USP/NF (HD5) manufactured by ICL were supplied by Signet 
Chemical Corporation, India. Eudragit E100 USP/NF and aerosil200 
USP/were manufactured and donated by Evonik industry, Germany. 
Sucralose manufactured and supplied by JK Sucralose, China. 
Aluminium hydroxide, mixed fruit flavour, was purchased from 
Central Drug House, Delhi, India was usedto USP/NF grade and 
Hydrochloric acid (SD fine chem Ltd.), Sod. di-hydrogen phosphate 
(SD fine chem Ltd.) and water were HPLC gradient grade. 
Preparation of ranitidine pellets 
MCC sphere 350micron were coated with ranitidine, followed by 3% 
seal coating by hypromellose and 5% functional coat by 
ethylcellulose pre-plasticized by 25% triethyl citrate (TEC) to retard 
the initial drug release in dosage form before administration. The 
coating was carried out by palm-glatt GPCG 1.1 using 1.0 mm 
atomizer spray at 38 °C product temperature with airflow of 70-80 
CFI and 8-12 g/min spray rate. The coating liquid was prepared as 
15% w/v TDS (total dispersed solid) for a batch size of 300g. 
Preparation of ranitidine alginate powder for suspension 
Protanal LFR5/60, Avicel PH105, sodium bicarbonate, calcium 
carbonate were passed through 425-micron sieve and aluminum 
hydroxide, magnesium hydroxide, avicelCL611, sucralose, mixed 
fruit flavour, aerosil 200 were passed through 250 micron 
separately and blended in turbula blender at 20rpm for 10 min. 
blended powders (R13) again pass through 425-micron sieve and 
blended with coated ranitidine HCl pellets equivalent to 300 mg of 
ranitidine for another 5 min. to achieve best homogeneity (table 1). 
Powder was reconstituted with 20 ml of water and used for further 
analysis.
  

















R1 250 125 375 267 110 97.5 375 10 50 10 
R2 500 125 375 267 110 97.5 375 10 50 10 
R3 750 125 375 267 110 97.5 375 10 50 10 
R4 500 125 375 267 110 97.5 188 10 50 10 
R5 500 125 375 267 110 97.5 563 10 50 10 
R6 500 125 375 134 110 97.5 375 10 50 10 
R7 500 125 375 201 110 97.5 375 10 50 10 
R8 500 500 375 267 110 97.5 375 10 50 10 
R9 500 800 375 267 110 97.5 375 10 50 10 
R10 500 125 563 267 110 97.5 375 10 50 10 
R11 500 125 750 267 110 97.5 375 10 50 10 
R12 500 125 375 267 220 195 375 10 50 10 
R13 750 125 375 201 110 97.5 375 10 50 10 
R13 0 p 125 375 201 110 97.5 375 10 50 10 
p
 
-formulation without Alginate 
Preparation of SGF (0.1NHCl-pH1.2) 
100 ml purified water was added in to 8.5 ml of concentrated 
hydrochloric acid and further added 700 ml of purified water. It was 
permitted to cool and made up to 1000 mlwith purified water. 
Viscosity 
The viscosity of the formulation was measured by using rheometer 
(model-Discovery HR-3, make-TA instruments). The rheometer is a 
precise instrument that contains the material of interest in a geometric 
configuration, controls the environment around it and applies and 
measures stress, strain and strain rate more accurately. The sample was 
applied on the lower fixed plate and geometry of 60 mm stainless steel 
parallel plate was used with a gap of 800micron. After equilibrating at 25 
°C for 1 min., a continuous shear rate of 0.1 to 500 s-1 was applied. The 
viscosity at lower shear rate was considered. 
Acid neutralizing capacity  
In vitro acid neutralizing capacity (ANC) helps to understand in vivo 
efficiency of the formulation to neutralize stomach acid. Formulation 
after reconstitution with 20 ml of water was diluted to 70 ml and mixed 
thoroughly for 1 min. and stirred at a speed of 300±30rpm. 30 ml of 1.0N 
hydrochloric acid was hereby added and stirred for another 15 min. 
Excess hydrochloric acid was titrated with 0.5N sodium hydroxide to 
attain a stable pH of 3.5. The number of mole equivalents of acid 
consumed (ACN) was calculated by the formula (1) [17, 18] 
Total mEq = (30 X NHCL) − (VNaOH X NNaOH)----------1 
pH of suspension 
pH was measured using a pH meter (Model-Five Easy Plus, make-
Mettler Toledo) after calibration with pH 7.00 and pH 4.00 buffer. 
The electrode surface was cleaned and placed in to20 ml 
reconstituted, suspension at room temperature (27±2 °C) and pH 
was noted after stabilization of signals.  
Raft weight, volume, and thickness 
The maximum dose of the formulation was transferred to 250 ml 
beaker containing 150 ml of 0.1NHCl heated and maintained at 37 °C 
temperature in a water bath for 30 min. The beaker used for raft 
formation was pre-weighed (W1) and the upper and lower position 
of the raft was marked from the outer side of the beaker. The total 
weight of the beaker after raft formation was measured (W2). The 
excess acid was decanted, and the raft was transferred to a weighing 
boat and after 30 sec., the weight of raft (W3) was measured by 
removing excess supernatant liquid. The remaining liquid was 
removed from the beaker and filled with water up to the upper mark 
and weighed (W4). The volume of raft was calculated by formula (2). 
Raft volume =  (W4 − W1) − (W2 − W1 − W3)------------2 
The thickness of the raft from the upper and lower marked position 
was measured by using calibrated vernier caliper, and noted in 
millimetre [7, 8]. 
Formation speed, coherence, and flotation of raft 
Raft formation was done as per the procedure mentioned previously 
and observed for speed, coherence and flotation. The formation 
speed was noted using calibrated stopwatch from the time of 
addition of the sample to 150 ml 0.1NHClto the formation of a 
floating raft. Flotation was evaluated as complete if all the insoluble 
materials rose to the surface. If insoluble materials sank to the 
bottom and remain there for 30 min., it was considered as partial 
flotation. The coherence of raft was assessed during removal of the 
raft from the beaker for weighing; Coherence is good if the raft was 
held substantially as a single mass, but poor if it gets broken into 
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two or more pieces of [7]. 
Raft strengths 
Raft was formed by adding a maximum recommended dose of 
formulation of sodium alginate in 250 ml beaker with internal 
diameter 65 mm containing 150 ml of 0.1N HCl preheated and 
maintained at 37 °C in a water bath; in which L-shaped probe was 
suspended such that the vertical arm of the probe hangs down the 
centre axis of the beaker and the horizontal arm was in the lower 
third of the acid. After 30 min., the beaker was removed from the 
water bath and transferred to Texture analyser (Model-TX plus, 
make-stable microsystem, UK). The ‘L’ shape probe was attached to 
the arm of texture analyser, and the probe was lifted through the raft 
at a speed of 5 mm/sec. The peak force during upward movement 
was recorded as raft strength in gram [7, 19]. The diagram of the raft 
strength measurement set up is shown in fig. 1. 
 
 
Fig. 1: Texture analyser: raft strength measurement. (TA. XT Plus, texture technologies, scarsdale, NY) 
 
Raft density 
A volume equivalent to 10g of a sample of the formulation was 
added to 100 ml measuring cylinder containing 50 ml of 0.1NHCl 
(pH 1.2). Raft volume was noted after 10 min, and density (g/ml) 
was calculated for each the formulation separately. Lower the 
density, the better the flotation; the density of formulation is 
expected to be less than the simulated gastric fluid [14].  
Resilience 
The anti-reflux formulation should have enough resilience to 
withstand in peristaltic waves of the stomach. The objective of this 
test was to understand the longevity of the raft under vigorous 
movement conditions. The sample formulation was placed in petri 
dish with ID 90 mm, and 17 mm depth and kept at the bottom of 
dissolution bowl (dissolution apparatus type-2, model-AT 7 Smart 
semi; make-SOTAX AG, Switzerland). 0.1NHCl preheated at 37 °Cwas 
transferred slowly into a bowl and allow raft formation for 30 min. 
The paddle rotation was kept at the 100rpmmimicking peristaltic 
movement. The rafts were assessed visually for gel size and 
coherence after regular intervals of agitation of 2, 5, 10, 20, 30, 45, 
and to a maximum of 60 min. or until the time at which the raft could 
no longer be detected. 
In vitro dissolution test 
The release of ranitidine from the raft forming suspension was 
studied using USP type-2 (paddle) apparatus (model-AT 7 Smart 
semi; make-sotax AG, Switzerland) at 37 °C and paddle rotating 
speed of 50rpm. This speed is slow enough to avoid any breakage of 
the raft and maintained with mild agitation condition believed to 
exist in vivo. Final formulation after reconstitution with 20 ml water 
was added to the dissolution bowl containing 0.1N hydrochloric acid 
(pH 1.2). Sample (5 ml) was taken out and replenished with fresh 
medium after 30, 45, 60, 120, 240, 360, 420 and 600 min. The 
amount of ranitidine in the withdrawn sample was measured by 
HPLC using Eclipse XDB C18 (150 mm×4.6 mm, 5 µm) column. 
Mobile phase A-2% tri-ethanolamine at pH 3 adjusted with 
orthophosphoric acid and mobile phase B-100% methanol was used. 
The eluent was monitored with UV detector set at 313 nm at 1 
ml/min flow rate with injection volume 25 µl [20, 21]. Dissolution 
was carried out in three units (triplicate) and the standard deviation 
was calculated. A curve of percent ranitidine release against time 
was plotted to illustrate the drug release profile. 
Stability study 
This study was planned with an objective to understand the impact 
of time on quality attributes of the formulation. The optimized 
formulation (R13) was exposed to ambient condition (temperature-
25±2 °C, RH-60±5%) and accelerated condition (temperature-40±2 
°C, RH-75±5%) up to three months in aluminum sachet. All the 
samples were tested for assay, dissolution and compared with the 
initial result after 3 mo. The chromatogram of samples was 
compared and studied for the peak and its area under the integrated 
curve.
 
RESULTS AND DISCUSSION 
 
Fig. 2: Development of raft in 0.1N HCl at 37 °C; R13 less than 9 sec and other formulations between 9-20 sec 
Sheela et al. 




The viscosity of formulationR1, R2, and R3shows that the alginate 
acts as a viscosifying agent and helps to form a stable suspension. 
Formulation R2, R8, R9 have a different concentration of viscosifying 
agent, build up high viscosity y, but do not imply any positive effect 
on raft strength. All the formulation R1 to R13 have optimum 
viscosity without any significant variation (fig. 3). 
  
  
Fig. 3: Main effect plot for viscosity and a comparative bar chart of viscosity for all formulation 
 
Acid neutralizing capacity (ANC) 
ANC is very important to understand in vivo effect of the formulation 
to neutralize excess stomach acid. The existing marketed 
formulation has similar acid neutralization capacity which fall in the 
range of 15 to 35 mEq [7]. The formulation expected to have better 
acid neutralization to treat GERD symptoms effectively. Alginates 
neutralize stomach acid up to a certain extent; higher concentration 
helps to achieve better neutralization. The higher concentration of 
alkalizing agent sodium bicarbonate (R6, R7), aluminum hydroxide, 
magnesium hydroxide (R12, R13) and calcium carbonate (R4, R5) 
have a positive effect on the acid neutralization, however higher 
concentration shows a negative effect on raft strengths. Hence it is 
very important to use an alkalizing agent at an optimum level (fig. 4). 
 
  
Fig. 4: Main effect plot of acid neutralization capacity (ANC) and it’s a comparative bar chart 
 
pH 
All the formulations has pH between 9.3 to 9.5 without any significant 
variation. The slightly higher pH is justifiable for the formulation 
intended for antacid and anti-reflux action. 
Raft weight and volume 
Weight and volume are a physical phenomenon, understood after raft 
formation in 0.1NHCl. The mechanism of action of the anti-reflux 
formulation is to act as a physical barrier at oesophageal sphincter to 
prevent acid reflux in the oesophagus. So, it is very necessary to 
evaluate and understand the physical strength of raft. The volume and 
weight are the physical parameters and are observed higher variation 
in results. The main effect plot of all the formulations for weight and 
volume implies that alginate has an impact on the weight and volume 
of raft and responsible to obtain higher weight and volume (fig. 5). 
 
  





















Avicel 611 MCC PH105 Sodium Bicarbonate Alluminium hydroxide Calcium carbonate
Main Effects Plot for Viscosity
Fitted Means





























Avicel 611 MCC PH105 Sodium Bicarbonate Alluminium hydroxide Calcium carbonate
Main Effects Plot for Acid Neutralizing capacity
Fitted Means




















Avicel 611 MCC PH105 Sodium Bicarbonate Alluminium hydroxide Calcium carbonate
Main Effects Plot for Weight
Fitted Means



















Avicel 611 MCC PH105 Sodium Bicarbonate Alluminium hydroxide Calcium carbonate
Main Effects Plot for Volume
Fitted Means
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Formation speed, coherence and flotation of raft 
Raft formation speed was observed while formation; and coherence 
and flotation was observed after raft formation which has 
significance in the onset of anti-reflux action. All the formulations 
have shown the onset of anti-reflux action less than 20 seconds, with 
proper coherence and flotation; except formulation R6 with 133 mg 
of NaHCO3
Raft strengths and density 
and formulation R3 with 750 mg of alginate has not 
shown uniform coherence.  
Raft strength is a very important quality attribute to understand the 
mechanism of anti-reflux action. The alginate formulation in contact 
with stomach acid forms a raft, which acts as a surrogate for 
oesophagus sphincter. The main effect plot (Fig.6) of raft strength 
reveals that the formulation (R3, R13) have higher raft strengths 
and lower density in comparison with other formulations. However, 
formulation R3 has not shown effective coherence and may fail to 
act against reflux in stomach. Whereas, formulation R13 has raft 
strengths of 17±1g, which is better than any available marketed 
products [7]. The concentration of alginate is critical in the 
formulation for raft strength. Raft strength and density are inversely 
proportional to each other. 
 
  
Fig. 6: Main effect plot for strengths and density of raft 
 
Possible interaction has been observed in the interaction plot 
between alginate and alkalizing agent (sodium bicarbonate, 
calcium carbonate) with respect to raft strength. An alkalizing 
agent like bicarbonate and hydroxide at higher concentration 
has shown negative interaction with sodium alginate, which 
results to loss of raft strength but have been used even in the 
commercially available anti-reflux product in the market to 
maintain its ANC [7]. 
The counterplot helps us to understand the design space of the alkalizing 
agent in the formulation. The counterplot shows that sodium 
bicarbonate at a lower concentration (200 mg to 250 mg) and alginate at 
higher concentration ( ≥ 750 mg) gives stronger raft strength(>16g). 
Calcium carbonate within a specific range (350 mg to 400 mg) gives 
better raft strength, whereas, hydroxides of aluminum and magnesium 
are not contributing positively to the raft strength and hence 
recommended to use at a lower level (fig. 7 and fig. 8). 
 
  
Fig. 7: Counter plot of NaHCO3, alginate, Al(OH)3, Mg(OH)2 
 
with raft strengths 
Raft resilience 
Raft resilience of formulation (R1) with 250 mg of sodium alginate 
and formulation (R4) with 188 mg calcium carbonate has shown 
lower resilience than other formulations. The formulation (R13) 
with 750 mg of sodium alginate and 375 mg CaCO3
In vitro dissolution test 
has shown good 
resilience. Moreover, formulation (R13) which was tested for in vitro 
dissolution shown resilience up to 10 h. Resilience and raft strength 
is directly proportional to each other, which is much better than the 
commercially available anti-reflux products [7]. 
The in vitro results show that formulation R3 and R13 have good 
quality attributes with respect to raft strength and ANC. Formulation 
R3 fails to have good coherence as compared to formulation R13. 
Considering all the quality attributes, formulation R13 has achieved 
excellent raft quality attributes and was studied further for in vitro drug 
release. The cumulative percentage release of ranitidine from ranitidine 
suspension (R13) with alginate and without alginate is summarized in 
table 2. The ranitidine suspension without alginate (R13p) does not form 
raft and shows immediate release without any control over the release 
rate. The formulation with alginate (R13) shows zero-order controlled 
release in 0.1N HCl up to 10 h (table 2, fig. 9). 
Stability study 
The optimized formulation (R13) was sealed in aluminium sachet 
and exposed to accelerated and ambient conditions and analysed for 
drug release. The release profile of ranitidine after three months as 
compared to that of initial has shown (fig. 10, table 3) no significant 
change and thus follows the same release pattern. The 
chromatogram of both was compared to understand any change in 
the potency (table 4). 
Further, there are no significant changes observed in drug release 
even after three months of exposure to accelerated stability 

























Avicel 611 MCC PH105 Sodium Bicarbonate Alluminium hydroxide Calcium carbonate
Main Effects Plot for Raft strengths
Fitted Means


















Avicel 611 MCC PH105 Sodium Bicarbonate Alluminium hydroxide Calcium carbonate
Main Effects Plot for Density
Fitted Means






























Contour Plot of Raft strengths vs Sod. Alginate, Sodium Bicarbonate



































Contour Plot of Raft strengths vs Alluminium hydro, Calcium carbonat
Worksheet: Worksheet 3; Sangmesh
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sufficiently be stable up to 6 mo at the ambient condition of temperature and humidity (25±2 °C, RH-60±5%). 
 
 
Fig. 8: Interaction plot for raft strengths 
 































R1 14±2 1 1* 16±4 * 25±5 52±2 14±1 7±3 40 0.56±0.1 0.0089±0.2 9.3±0.1 
R2 10±3 1 1* 19±3 * 38±4 62±3 16±2 16±4 >60 0.37±0.3 0.0192±0.3 9.3±0.3 
R3 20±1 0 1* 21±5 * 48±6 84±3 17±1 19±2 >60 0.29±0.4 0.0328±0.3 9.3±0.2 
R4 7±4 1 1* 20±3 * 37±4 60±2 11±2 9±3 55 0.38±0.3 0.0273±0.4 9.3±0.1 
R5 18±2 1 1* 17±4 * 43±4 70±3 20±2 10±3 >60 0.36±0.5 0.0662±0.3 9.5±0.3 
R6 18±3 0 1* 15±2 * 34±5 56±3 11±1 15±4 >60 0.31±0.3 0.0542±0.2 9.3±0.2 
R7 10±2 1 1* 17±4 * 37±6 64±2 14±2 17±3 >60 0.36±0.2 0.0153±0.2 9.3±0.3 
R8 10±1 1 1* 17±5 * 38±5 54±2 16±1 11±4 >60 0.37±0.3 0.0331±0.3 9.3±0.3 
R9 13±3 1 1* 16±3 * 37±5 60±1 16±1 15±2 >60 0.33±0.4 0.1097±0.2 9.3±0.2 
R10 10±3 1 1* 22±3 * 40±4 64±3 16±2 12±4 >60 0.34±0.2 0.0236±0.3 9.3±0.2 
R11 9±4 1 1* 22±5 * 43±3 72±2 16±1 15±3 >60 0.37±0.3 0.0185±0.2 9.3±0.3 
R12 10±2 1 1* 19±4 * 42±5 58±1 20±1 12±2 >60 0.33±0.3 0.0574±0.3 9.3±0.2 
R13 9±2 1 1* 19±2 * 43±4 62±3 17±1 18±2 >60 0.29±0.4 0.0703±0.2 9.3±0.2 
R13 No raft formation p 
MF-mixed fruit, ANC-acid neutralization capacity. Note-1*-good/complete, 0*-Not good/partial, (value representthe mean±SD, n =3) 
 
 
Fig. 9: In vitro release of ranitidine with alginate (R13), and without alginate suspensions (R13p); mean±SD, n=3 





















































Interaction Plot for Raft strengths
Data Means

























% Ranitidine release Vs Time, USP-II, rpm-50, 0.1N HCL, n=3
Comparative release of Ranitidine in suspension with and without alginate  
Worksheet: Worksheet 4; Sangmesh
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Fig. 10: In vitro release of R13 suspension initially and after 3 months at 25/60 and 40/75; mean±SD, n=3 
 
Table 3: Percent cumulative release of ranitidine alginate suspension (R13) in vitro dissolution study 
Time (min) Ranitidine suspension_R13p Initial_R13 3 Mo 25-60_R13 3 Mo 40-75_R13 
PCR±SD PCR±SD PCR±SD PCR±SD 
5 29.3±14.3 16.3±0.3 17.0±1.3 17.6±1.1 
10 41.0±19.3 23.5±1.5 30.6±3.8 36.9±2.5 
30 51.9±21.9 32.0±3.0 37.1±4.5 47.4±2.9 
45 57.9±23.7 36.2±0.8 44.1±4.3 52.4±2.4 
60 64.0±22.1 43.9±3.3 49.4±5.3 58.7±2.3 
120 90.2±0.6 50.2±2.9 66.9±10.8 66.5±2.9 
240 95.5±0.5 66.5±4.8 77.4±7.9 76.1±4.3 
360 97.0±0.6 72.3±0.7 81.4±6.2 79.6±4.2 
480 99.0±1.3 85.6±0.7 82.8±5.6 81.3±3.3 
600 99.6±1.0 95.3±1.0 99.6±1.4 94.3±1.9 
(PCR-Percent cumulative release represents; SD-standard deviation, value represent mean±SD, n =3) 
 
Table 4: Chromatogram of ranitidine HCl at initial and after three months of stability 
Condition-Initial 
Concentration-373.33 ppm 
Flow rate-1 ml/min 
Detector-UV at 313 nm 
Injection volume-25 µl 
Area of peak-18482 (rt-3.65 min) 
 
Condition-3Month at 25 °C/RH60% 
Concentration-373.33 ppm 
Flow rate-1 ml/min 
Detector-UV at 313 nm 
Injection volume-25 µl 




























% Ranitidine release Vs Time, USP-II, rpm-50, 0.1N HCL, n=3
Worksheet: Worksheet 4; Sangmesh
Comparative release of Ranitidine in suspension at initial with 3 Month stability 
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Condition-3Month 40 °C/RH75% 
Concentration-373.33 ppm 
Flow rate-1 ml/min 
Detector-UV at 313 nm 
Injection volume-25 µl 




The developed powder for suspension has shown triple action 
combining antacid, anti-reflux and controlled release of active drug 
which normally necessitates the intake of three different drugs. The 
in vitro evaluation shows that formulation R13 containing 300 mg of 
ranitidine and 750 mg of alginate has sufficient strength with higher 
alkalizing agent than other formulations. This formulation even has 
better acid neutralization effect without compromising on the 
strength of the raft likely to occur with increasing concentration of 
alkalizing agent. The viscosity is satisfactory to hold the dispersed 
insoluble materials in the media uniformly. However, sedimentation 
would occur on prolonged standing of suspension and hence 
recommended to use immediately after reconstitution. In addition, 
flotation, pH coherence, weight and volume of raft facilitate better 
raft strength. The release profile in 0.1N HCl favours the release of 
ranitidine in stomach acid at a controlled rate up to 10 h. The 
stability study implies that the formulation is stable up to three 
months of accelerated and ambient conditions of temperature and 
humidity. Thus, this novel formulation has greater potential to be 
developed as a multifunctional drug for the treatment of GERD.  
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